ARA-290 (cibinetide) research and evidence overview

ARA-290 is further along than most peptides discussed on this site: it has real randomised, double-blind, placebo-controlled human trials with published numbers, run by academic anaesthesiology and pulmonology groups in the Netherlands, the UK and the US. What it does not have is a confirmatory phase 3 trial, an approval, or a result in a large unselected population. Every published trial is small — 22, 64, and a phase 2 diabetes cohort — and most primary endpoints are surrogate measures of nerve structure rather than hard clinical outcomes.

Erythropoietin protects injured tissue, but it also makes red blood cells, and using it as a tissue-protective drug means accepting thrombotic risk. ARA-290 is an 11-amino-acid peptide built from the helix B surface of erythropoietin — the face that engages what its developers call the innate repair receptor — without the part that drives erythropoiesis. The whole research programme is a test of whether those two functions can be separated. On the safety side, the trials below found no haematocrit signal, which is the first thing that would sink the concept.

The first randomised human result came in sarcoidosis-associated small-fibre neuropathy: 22 patients with a neuropathy diagnosis and a spontaneous pain score of at least 5, randomised to intravenous ARA 290 2 mg three times weekly (n=12) or placebo (n=10) for four weeks (Heij et al., Molecular Medicine 2012, PMID 23168581).

The Small Fiber Neuropathy Screening List score improved significantly more with ARA 290 (Δ −11.5 ± 3.04 versus Δ −2.9 ± 3.34, p<0.05), as did the pain and physical-functioning dimensions of the SF-36. Two results cut the other way and are worth naming: the Brief Pain Inventory and Fatigue Assessment Scale improved significantly but equivalently in both arms, and depressive symptoms did not change. No safety concerns were raised. A 22-patient exploratory trial where the headline endpoint moves and the pain inventory does not is a signal, not a demonstration.

The largest published trial is a 28-day phase 2b study in 64 people with sarcoid-associated small nerve fibre loss and neuropathic pain, comparing cibinetide 1, 4, or 8 mg/day against placebo, with change in corneal nerve fibre area measured by corneal confocal microscopy as the primary endpoint (Culver et al., Investigative Ophthalmology & Visual Science 2017, PMID 28475703).

Only the 4 mg arm separated from placebo: placebo-corrected mean change in corneal nerve fibre area was 697 µm² (95% CI 159–1236, p=0.012), versus 109 (95% CI −429–647) at 1 mg and 431 (95% CI −130–992) at 8 mg. Regenerating intraepidermal GAP-43+ fibres increased in the same 4 mg group (p=0.035), and changes in nerve fibre area correlated with GAP-43+ change and with six-minute walk distance. Pain improved in all groups; in the moderate-to-severe pain subgroup, the placebo-corrected decrease at 4 mg did not reach significance (p=0.157).

A dose-response that peaks in the middle and fades at the highest dose is not disqualifying — inverted-U responses occur — but it is the pattern that most often fails to replicate, and the authors themselves framed the trial as validating corneal nerve fibre area as a surrogate endpoint.

A phase 2 study extended the peptide to type 2 diabetes with painful neuropathy: self-administered subcutaneous ARA 290 4 mg or placebo daily for 28 days, with subjects followed a further month off treatment (Brines et al., Molecular Medicine 2015, PMID 25387363). Treated subjects showed improvement in HbA1c and lipid profiles sustained across the 56-day observation period, significant improvement in neuropathic symptoms on the PainDetect questionnaire, and — in the subgroup whose baseline corneal nerve fibre density was more than one standard deviation below normal — a significant increase in nerve fibre density versus no change on placebo. No safety issues were identified.

Three caveats sit on that result. The corneal-nerve finding is a post-hoc-flavoured subgroup analysis. Several authors are employees of the company developing the peptide. And the authors' own conclusion is deliberately modest — that ARA 290 "may benefit" both endpoints and "deserves continued clinical evaluation."

ARA-290 is a good case study in what early-phase success looks like: consistent direction of effect across three independent trials, a plausible and testable mechanism, a clean safety record at the doses tested, and endpoints that are mostly structural or questionnaire-based rather than outcomes patients feel over years. The trials are individually too small to exclude chance, the two most favourable ones share authorship with the sponsor, and no confirmatory programme has published a result. Marketing that describes ARA-290 as "clinically proven" for neuropathy overstates what a 22-person pilot and a 64-person surrogate-endpoint study can carry.